In accordance with Section 287(a) of Title 35 of the United States Code, the following list identifies Sanofi’s rights in U.S. patents associated with the listed products. This list may be a subset of Sanofi’s rights in U.S. patents directed to the relevant product. The absence of a product or a U.S. Patent number from this list does not constitute a waiver of Sanofi’s patent, trademark, or other intellectual property rights.
-
Alprolix®
[Coagulation Factor IX (Recombinant), Fc Fusion Protein]
U.S. Patent No. 7,404,956
U.S. Patent No. 10,588,949
U.S. Patent No. 10,058,480
U.S. Patent No. 10,849,823ALTUVIIIO™
[Antihemophilic Factor (Recombinant),
Fc-VWF-XTEN Fusion Protein-ehtl]
U.S. Patent No. 8,673,860
U.S. Patent No. 9,371,369
U.S. Patent No. 10,138,291
U.S. Patent No. 10,421,798
U.S. Patent No. 11,192,936
U.S. Patent No. 11,370,827Cablivi®
(caplacizumab-yhdp)
U.S. Patent No. 7,807,162
U.S. Patent No. 8,372,398
U.S. Patent No. 10,035,862Caprelsa®
(vandetanib) Tablets
U.S. Patent No. 8,067,427Cerdelga®
(eliglustat) capsules
U.S. Patent No. 7,196,205
U.S. Patent No. 11,458,119Dupixent®
(dupilumab) Injection
is a product in collaboration with Regeneron.
U.S. Patent No. 7,608,693
U.S. Patent No. 8,945,559
U.S. Patent No. 10,435,473
U.S. Patent No. 9,238,692
U.S. Patent No. 11,059,896
U.S. Patent No. 8,735,095Eloctate®
[Antihemophilic Factor (Recombinant), Fc Fusion Protein]
U.S. Patent No. 7,404,956
U.S. Patent No. 8,329,182
U.S. Patent No. 9,623,088
U.S. Patent No. 10,058,480
U.S. Patent No. 10,849,823Enjaymo™
(sutimlimab-jome) injection, for intravenous use
U.S. Patent No. 8,877,197
U.S. Patent No. 8,945,562
U.S. Patent No. 10,450,382Jevtana®
(cabazitaxel) Injection
U.S. Patent No. 7,241,907Kevzara®
(sarilumab) Injection is a product in collaboration with Regeneron.
U.S. Patent No. 7,582,298
U.S. Patent No. 10,072,086
U.S. Patent No. 11,098,127
U.S. Patent No. 8,183,014Nexviazyme™
(avalglucosidase alfa-ngpt)
U.S. Patent No. 8,759,501Rezurock®
(belumosudil) tablets
U.S. Patent No. 8,357,693Sarclisa®
(isatuximab-irfc)
U.S. Patent No. 8,153,765Soliqua® 100/33
(insulin glargine and lixisenatide) injection
100 Units/mL and 33 mcg/mL
U.S. Patent No. RE45,313
U.S. Patent No. 9,526,764
U.S. Patent No. 10,117,909
U.S. Patent No. 10,029,011
U.S. Patent No. 9,707,176
U.S. Patent No. 9,717,852Toujeo®
(insulin glargine injection)
300 Units/mL
U.S. Patent No. 9,345,750
U.S. Patent No. 11,213,628
U.S. Patent No. 10,369,291Zaltrap®
(ziv-aflibercept) Injection for Intravenous Infusion
U.S. Patent No. 8,110,546
U.S. Patent No. 8,710,004 -
MenQuadfi™
(Meningococcal [Groups A, C, Y, W] Conjugate Vaccine)
U.S. Patent No. 11,147,866
Please See Full Prescribing Information, including Boxed Warning, for Caprelsa, Jevtana, Kevzara, Nexviazyme, Zaltrap.